Scientific and regulatory development
Development plan, preclinical and clinical strategy, CMC, quality, CDMOs, regulatory roadmap and technical gates.
Biotech advisory · Venture & product readiness
From promising paper to investable biotech.
Senior advisory that sequences the critical decisions — scientific, legal, commercial and financial — that turn a technology into a company an investor can underwrite.
Experience
Projects that have already come through.
Projects and companies across pharma, biotech, clinical research, medical nutrition and digital health — teams that need scientific judgement, market sense and the ability to execute.
The problem
The science can be brilliant and the project still be a mess.
No plan, no legal structure, and a story that does not survive three questions from an investor. A biotech is not built on good science alone. It is built on decisions taken in the right order.
01
No development plan
Promising scientific data, but no clear development plan.
02
Fronts pulling apart
Science, regulation, market and funding pulling in different directions.
03
No legal structure
No legal structure for the spin-off, the founders, the IP or the contracts.
04
Projections on demand
Financial projections built because a spreadsheet asked for them.
05
Roadmaps without gates
Roadmaps with no gates, no ranked risks and no owners.
06
Not a company yet
A publication is not a company. A patent is not a round.
What we do
Biotech advisory for the decisions you cannot improvise.
We structure the project across connected fronts. A bad legal decision hits the funding; a bad market assumption hits the development plan. Nothing here is independent.
Legal, IP and corporate structure
Spin-offs, shareholder agreements, intellectual property, contracts, licensing, tech transfer and compliance.
Business, market and funding
Feasibility, market, competition, business plan, financial model, funding strategy and investor narrative.
Scientific communication
Scientific video, event broadcasting, web design and training material to explain and position the project.
The decision stack
Development & regulatoryPreclinical · CMC · Gates
Legal & IPSpin-off · Patents
Business & marketModel · Competition
FundingRunway · Grants · Equity
Advisory · the people
Strategic advisory, end to end.
Three senior disciplines sequence the decisions that make a biotech investable — from the science and its protection to the business case the investor signs.
01
Scientific and regulatory development
From the promising experiment to the asset roadmap: target product profile, evidence strategy, regulatory route and CMC, sequenced from preclinical to first dose in humans.
- Target product profile (TPP)
- Preclinical and evidence plan
- Regulatory roadmap and gate map
- CMC and manufacturing strategy
02
Legal and intellectual property
We protect the asset and structure the company: freedom to operate, patents, corporate structure, licensing, and the regulatory and data compliance that gets due-diligenced.
- Corporate structure and shareholder agreements
- Spin-off and technology transfer
- IP strategy and patent plan
- Biotech contracts (NDA, CRO, CDMO, licensing)
03
Business, market and funding
We build the case that raises capital: market and competition, business model, financial plan, funding strategy and investor narrative — from the public grant to the Series A.
- Feasibility and market analysis
- Business plan and financial model
- Funding strategy (public and private)
- Investor memo, pitch deck and data room
Programs
Packaged advisory, with a defined scope.
We do not sell blocks of hours. Every program has an objective, a scope and a set of deliverables — so you know what you get and when.
Venture Scan
A fast read of the project: scientific, legal, market and funding maturity, with the critical decisions ranked.
Venture Blueprint
The development and business plan sequenced gate by gate: milestones, risks, costs and owners, ready to execute.
Legal Biotech Kit
The legal structure that makes the technology fundable: company, shareholder agreement, IP and key contracts.
Investor Readiness Pack
The case an investor underwrites: business plan, financial model, investor memo, pitch deck and data room.
Maturity & Investability Report
An independent report on the maturity and investability of the asset, with a roadmap to close the gaps.
Fractional PMO
Part-time project direction: milestone, runway and risk tracking, with periodic reporting for the team and its investors.
Method
How we work.
First we think. Then we structure. Then we execute. We leave the magic to LinkedIn.
Diagnostic
We map the asset, the stage, the legal structure, the funding, the risks and the priorities.
Critical decision map
We identify what is actually blocking progress: scientific, regulatory, legal, financial and market decisions.
Development and business plan
A sequenced plan with milestones, gates, costs, owners, risks and deliverables.
Execution and expert support
We stay on the key calls: development, CDMOs, IP, contracts, funding and investors.
Tracking and reporting
We review progress, runway, milestones and risks, and prepare the reports for the team, the board and its investors.
Ensayo de toxicidad
Preclínico
185 k€
▲ en plazo
Solicitud PCT
Propiedad industrial
32 k€
● pendiente
Reunión de asesoramiento
Regulatorio · AEMPS
Mar ’27
▼ 6 sem.
Cierre de ronda
Inversión · Serie A
2.4 M€
▲ 8 % vs plan
Deliverables
What you get from working with Adbaio.
We do not deliver general recommendations. We deliver the structure to decide and move.
Strategic diagnostic+
Development roadmap+
Preclinical and clinical plan+
Regulatory strategy+
CMC and manufacturing plan+
Risk map+
Business plan+
Financial model+
Runway and scenarios+
Market analysis+
Competitive landscape+
Pitch deck, investor memo and data room+
Spin-off and company structure+
Shareholder agreements+
IP strategy+
Key contracts+
Periodic progress reports+
Tracking and reporting plan+
Team
A hybrid team for a hybrid problem
Building a biotech takes science, regulation, law, business, funding, market and execution. That is why the team is put together the way it is.
RM
Chief scientific officer. Over 25 years in pharma and biotech: drug development, CMC and scientific strategy.
Science · CMC
ÁÍ
Lawyer: contracts, corporate, R&D, pharmaceutical and administrative law, biotech legal support.
Legal · IP
AM
Business development, strategy, market and access. Customer strategy in pharma and biotech.
Business · Market
RÍ
Rubén Íñiguez Pérez
Digital training, audiovisual production and scientific communication.
Digital · Communication
Network of specialist collaborators
- Manish Sharma — Manufacturing · CMC
- Jaume Ruiz — Development · Business
- Karen Sánchez — Legal · Data
- Leire Zúñiga — Clinical trials
- Naiara Pineda — Finance
FAQ
Frequently asked questions
Do you only work with biotech startups?
No. We work with researchers, spin-offs, biotech startups, pharma and biotech companies, and projects in health, R&D, advanced therapies, medical devices and related technologies.
At what stage does it make sense to talk to you?
Early, above all: pre-spin-off, preclinical, preparing a proof of concept, raising funding or defining a roadmap. The sooner the critical decisions are put in order, the less the chaos costs.
How is an engagement structured?
Through programs with a defined scope and deliverables (see Programs), or as bespoke support. We almost always start with a diagnostic that ranks the priorities before committing to larger work.
Do you help with funding?
Yes. Business plan, financial model, investor narrative, pitch deck, investor memo, data room, term sheets and public or private funding strategy.
Do you handle legal work?
Yes. Corporate structure, spin-offs, shareholder agreements, intellectual property, contracts, licensing, technology transfer, sector regulation, data protection and due diligence.
Do you replace the scientific team?
No. We complement it with development judgement, legal structure, market sense, funding and tracking. The science stays with the team. So should the order.
Contact
Have a project and need advice?
Tell us where the project stands. Book a call or write to us through the form and we will come back with the next steps.
Promising science and too many loose pieces?
Tell us where the project stands and we will help you work out what it needs to move: development, legal, market, funding, or all of the above.
Book a diagnostic sessionOne call can save months aimed at the wrong question.